Luis Donaldo Gonzalez Morales

Prof. Luis Donaldo Gonzalez Morales

Biotecnología Farmacéutica y Biomedicina Molecular, Centro de Biotecnología Genómica-IPN, Reynosa, Tamaulipas, Mexico
+1
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Luis Donaldo Gonzalez MoralesLuis Donaldo Gonzalez Morales
Luis Donaldo Gonzalez Morales
ARAdriana Moreno Rodriguez Adriana Moreno Rodríguez
Adriana Moreno Rodriguez Adriana Moreno Rodríguez
LVLenci K. Vázquez-Jiménez
Lenci K. Vázquez-Jiménez
Timoteo Delgado MaldonadoTimoteo Delgado Maldonado
Timoteo Delgado Maldonado
Alfredo Juárez-SaldivarAlfredo Juárez-Saldivar
Alfredo Juárez-Saldivar
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Cutaneous leishmaniasis (CL) is a public health problem affecting more than 98 countries worldwide. No vaccine is available to prevent the disease, and available medical treatments cause serious side effects. Additionally, treatment failure and parasite resistance have made the development of new drugs against CL necessary. In this work, a virtual screening of natural products from the BIOFACQUIM and Selleckchem databases was performed using the method of molecular docking at the triosephosphate isomerase (TIM) enzyme interface of Leishmania mexicana (L. mexicana). Finally, the in vitro leishmanicidal activity of selected compounds against two strains of L. mexicana, their cytotoxicity, and selectivity index were determined. The top ten compounds were obtained based on the docking results. Four were selected for further in silico analysis. The ADME-Tox analysis of the selected compounds predicted favorable physicochemical and toxicological properties. Among these four compounds, S-8 (IC50 = 55 µM) demonstrated a two-fold higher activity against the promastigote of both L. mexicana strains than the reference drug glucantime (IC50 = 133 µM). This finding encourages the screening of natural products as new anti-leishmania agents.

3 March 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LVLenci K. Vázquez-Jiménez
Lenci K. Vázquez-Jiménez
Alfredo Juárez-SaldivarAlfredo Juárez-Saldivar
Alfredo Juárez-Saldivar
MCManuel Chan-Bacab
Manuel Chan-Bacab
Timoteo Delgado MaldonadoTimoteo Delgado Maldonado
Timoteo Delgado Maldonado
Luis Donaldo Gonzalez MoralesLuis Donaldo Gonzalez Morales
Luis Donaldo Gonzalez Morales
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Leishmania mexicana (L. mexicana) is a causal agent of cutaneous leishmaniasis (CL), a “Neglected disease”, for which the search for new drugs is a priority. Benzimidazole is a scaffold used to develop antiparasitic drugs; therefore, it is interesting molecule against L. mexicana. In this work, a ligand-based virtual screening (LBVS) of the ZINC15 database was performed. Subsequently, molecular docking was used to predict the compounds with potential binding at the dimer interface of triosephosphate isomerase (TIM) of L. mexicana (LmTIM). Compounds were selected on binding patterns, cost, and commercial availability for in vitro assays against L. mexicana blood promastigotes. The compounds were analyzed by molecular dynamics simulation on LmTIM and its homologous human TIM. Finally, the physicochemical and pharmacokinetic properties were determined in silico. A total of 175 molecules with docking scores between −10.8 and −9.0 Kcal/mol were obtained. Compound E2 showed the best leishmanicidal activity (IC50 = 4.04 µM) with a value similar to the reference drug pentamidine (IC50 = 2.23 µM). Molecular dynamics analysis predicted low affinity for human TIM. Furthermore, the pharmacokinetic and toxicological properties of the compounds were suitable for developing new leishmanicidal agents.

1 June 2024 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Timoteo Delgado MaldonadoTimoteo Delgado Maldonado
Timoteo Delgado Maldonado
Luis Donaldo Gonzalez MoralesLuis Donaldo Gonzalez Morales
Luis Donaldo Gonzalez Morales
AJAlfredo Juarez-Saldivar
Alfredo Juarez-Saldivar
ELEdgar E. Lara-Ramírez
Edgar E. Lara-Ramírez
GRGuadalupe Rojas-Verde
Guadalupe Rojas-Verde
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Background: In the last years, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused more than 760 million infections and 6.9 million deaths. Currently, remains a public health problem with limited pharmacological treatments. Among the virus drug targets, the SARS-CoV-2 spike protein attracts the development of new anti-SARS-CoV-2 agents. Objective: The aim of this work was to identify new compounds derived from natural products (BIOFACQUIM and Selleckchem databases) as potential inhibitors of the spike receptor binding domain (RBD)-ACE2 binding complex. Methods: Molecular docking, molecular dynamics simulations, and ADME-Tox analysis were performed to screen and select the potential inhibitors. ELISA-based enzyme assay was done to confirm our predictive model. Results: Twenty compounds were identified as potential binders of RBD of the spike protein. In vitro assay showed compound B-8 caused 48% inhibition at 50 μM, and their binding pattern exhibited interactions via hydrogen bonds with the key amino acid residues present on the RBD. Conclusion: Compound B-8 can be used as a scaffold to develop new and more efficient antiviral drugs.

1 February 2026 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Timoteo Delgado MaldonadoTimoteo Delgado Maldonado
Timoteo Delgado Maldonado
Luis Donaldo Gonzalez MoralesLuis Donaldo Gonzalez Morales
Luis Donaldo Gonzalez Morales
GVGilberto Vargas-Salas
Gilberto Vargas-Salas
MVMa Guadalupe Rojas Verde
Ma Guadalupe Rojas Verde
EOEyra Ortiz-Perez
Eyra Ortiz-Perez
Gildardo RiveraGildardo Rivera
Gildardo Rivera
Background: To date, COVID-19 has caused over 772 million cases, with approximately 7 million deaths, according to the World Health Organization. Therefore, there is a need to develop new drugs to address the challenges posed by this disease. Objective: To propose new antiviral agents based on the natural product curcumin as potential protein-protein interaction inhibitors between the SARS-CoV-2 spike receptor binding domain (RBD) and the ACE2 receptor. Methods: A curcumin-based virtual screening was performed (Tanimoto coefficient= 0.9), and molecular docking analysis were carried out using the RBD as a receptor. Molecular dynamics (MD) using GROMACS were conducted for 120 ns. The SwissADME server was used to predict pharmacokinetics. To validate predictions, an in vitro enzyme assay measuring the relative inhibition of the interaction between the RBD and the ACE2 receptor was performed. Results: More than 1300 ligands were evaluated through molecular docking. The docking results were analyzed, and the ligands were classified according to their score and profile of interactions with residues of the RBD of the SARS-CoV-2 S glycoprotein. The top ten with the best scores and interactions were selected to verify the commercial availability. The lead compound Cu-1 demonstrated significant interactions with the RBD and stability in MD simulations, was acquired and evaluated in vitro. Compound Cu-1 inhibited 36 ± 0.7 % the interaction between the SARSCoV- 2 spike and the ACE2 receptor. In addition, Cu-1 was shown to have an acceptable druglikeness and pharmacokinetic profile. Conclusion: Curcumin provides a scaffold for identifying novel compounds with potential antiviral activity. Further studies on compound Cu-1 could yield on optimizing its structure to increase activity targeting the RBD of the S glycoprotein.